-
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy
Vennegoor, A., Rispens, T., van Oosten, B. W., Wattjes, M. P., Wondergem, M. J., Teunissen, C. E., van der Kleij, D., Uitdehaag, B. M. J., Polman, C. H. & Killestein, J., 2015, In: Multiple sclerosis (Houndmills, Basingstoke, England). 21, 4, p. 481-484Research output: Contribution to journal › Article* › Academic › peer-review
-
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
Vennegoor, A., Rispens, T., Strijbis, E. M., Seewann, A., Uitdehaag, B. M., Balk, L. J., Barkhof, F., Polman, C. H., Wolbink, G. & Killestein, J., 2013, In: Multiple sclerosis (Houndmills, Basingstoke, England). 19, 5, p. 593-600Research output: Contribution to journal › Article* › Academic › peer-review
-
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped
Rispens, T., Vennegoor, A., Wolbink, G. J., Polman, C. H. & Killestein, J., 2012, In: MULTIPLE SCLEROSIS JOURNAL. 18, 6, p. 899-901Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
